WASHINGTON (AP) — Federal regulators say approval of the first generic version of cancer drug Doxil will help resolve a lingering shortage triggered by manufacturing deficiencies.
The shortage of the Johnson & Johnson injectable medication, made under contract by Ben Venue Laboratories, has continued on and off for a few years. It's resulted in rationing, with some patients with ovarian and other cancers getting less-effective care, and disrupted studies testing Doxil against possible new treatments.
The Food and Drug Administration says it's approved a generic version, called doxorubicin, made by Sun Pharma Global FZE. Last February, the FDA authorized temporary importation from India of a brand-name version, called Lipodox, also made by Sun Pharma. It's a subsidiary of an Indian drugmaker.
Meanwhile, J&J continues to seek a contract manufacturer to replace Ben Venue.
Breaking: Federal court blocks EPA rule on waterways - Hot Air
Katie Pavlich - Hillary: My Republican Opponents Treat Women Just Like Terrorists Do
Boom! Obama gets devastating reminder after blasting New Orleans' longtime 'structural inequality'
Vox "Smart Take" Pushes Gun Confiscation. Here's What Would Happen If They Tried. - Bearing Arms - 2nd Amendment, Gun Confiscation
RIP, the Jeb Bush 2016 Campaign | RedState
Small But Honest Columnist Again Forced to Correct Highest-Rated Show on Cable TV | Human Events
Larry Kudlow - Donald Trump: A 21st Century Protectionist Herbert Hoover